Skip to content
中文产业新闻精选评分63Chinese source

恒瑞ANGPTL3单抗芮弗西拜单抗HoFH三期研究入选ESC 2026 LBA，LDL-C相对安慰剂下降64.2%

ESC 2026 LBA｜HoFH患者LDL-C降幅相对安慰剂达64.2%！恒瑞医药创新药芮弗西拜单抗Ⅲ期研究重磅亮相

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.